Samvel B. Gasparyan

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado et al. · The Lancet Diabetes & Endocrinology · 2021 · 235 citations · Full text

Cardiovascular Disease, Cardiometabolic Risk, Cardiovascular Pharmacology +11

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF

Pardeep S. Jhund, Piotr Ponikowski, Kieran F. Docherty et al. · Circulation · 2021 · 58 citations · Full text

Effects of <b>da</b> pagliflozin on prevention of major clinical events and recovery in patients with <b>re</b> spiratory failure because of COVID‐ <b>19</b> : Design and rationale for the DARE‐19 study

Mikhail Kosiborod, Otávio Berwanger, Gary G. Koch et al. · Diabetes Obesity and Metabolism · 2020 · 46 citations · Full text

Balcinrenone Plus Dapagliflozin in Patients with Heart Failure and Chronic Kidney Disease: Results from the Phase 2b MIRACLE Trial

Carolyn S.P. Lam, Lars Køber, Koichiro Kuwahara et al. · European Journal of Heart Failure · 2024 · 34 citations · Full text

Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression

Hiddo J.L. Heerspink, Niels Jongs, Patrick Schloemer et al. · Journal of the American Society of Nephrology · 2023 · 27 citations · Full text